Viva Biotech Holdings · HKEX:1873
Viva Biotech — FY2021 Earnings Presentation
28 slides from Viva Biotech's earnings presentation, Mar 29, 2022
Slide 1: Viva Biotech 2021 Annual Results
Viva Biotech 2021 Annual Results 29 March 2022 Shanghai, China
Slide 2: Forward-Looking Statements; Use of Non-IFRS Financial Measures
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our managemen
Slide 3: Contents
01 Business Highlights 02 Financial Performance CONTENTS 03 Future Strategies Q&A Session
Slide 4: World Leading One-stop Drug Research and Production Platform
World Leading One-stop Drug Research and Production Platform CDMO Research and Production EFS Investment & Incubation CRO Business Business Business Focus on FIC's Discover business, take Provide innovative drug partners with small Focus on discovering and investing SBDD as the core to drive FBDD, d
Slide 5: Continued to Build Technology Barriers, Improved CRO-CDMO Service Capabilities
Continued to Build Technology Barriers, Improved CRO-CDMO Service Capabilities as a One-stop Platform SBDD FBDD Compound design Viva Fragment Library Viva Compound CADD Library Computational Chemistry & ASMS screening platform SEC-ASMS Biology Fragment Library 1 Screening / HTS AI technology assiste
Slide 6: Overview: Business Highlights
Overview Business Highlights l Revenue: RMB2104 million, +201.9% YOY l Gross profit: RMB651 million, +113.5% YOY l Adjusted net profit: RMB353 million, +39.7% YOY l Adjusted basic earnings per share: HK$0.21 l The Group’s total no. of clients: 1820, widely located in North America, Europe 2104 and A
Slide 7: PART 1: Business Highlights
CV iva PART 1: Business Highlights
Slide 8: Overview: CRO Drug Discovery Services with Rapid Growth
Overview CRO: Drug Discovery Services with Rapid Growth l Revenue: RMB740 million, +68.6% YOY CAGR 31.69% l Adjusted Gross profit: RMB343 million, +63.6% YOY 85.8 l Revenue from Top 10 customers accounted for 26.8%, decreased by 9.45pp YOY, representing a continued optimization of the structure l Re
Slide 9: CRO: Drug Discovery Services with Rapid Growth and Favorable Backlog
CRO: Drug Discovery Services with Rapid Growth and Favorable Backlog Order backlog: +58.9% No. of CRO R&D staff: +48.2% RMB 100 million 1211 9.65 817 6.07 614 3.49 2019 2020 2021 2019 2020 2021 Served Top 10 global pharmaceutical companies No. of CRO customers: +90% 2021 1032 (by reported total reve
Slide 10: CRO: Expanding Scale with Targets and Protein Structures Delivered
CRO: Expanding Scale with No. of Targets and Protein Structures Delivered Hit Record High Radiation source usage No. of targets and protein structures delivered Hours 2021 1934 2020 l Independent targets: +226 1428 2019 1215 l Cumulative Number: 1810 l Use 12 synchrotron radiation source centers aro
Slide 11: Overview: CDMO R&D and Production Services
Overview CDMO R&D and Production Services l Langhua’s revenue: RMB1364 million, -10.2% YOY l Langhua’s adjusted gross profit: RMB329 million, -25.4% YOY l CDMO: revenue RMB730 million, -15.22% YOY; gross profit margin 430 38.22%, +2.05pp YOY 373 l API: revenue RMB261 million, +15% YOY; gross profit
Slide 12: CDMO: Increased Investment in R&D & Production Capacity
CDMO : Increased Investment in R&D & Production Capacity Revenue and gross profit from CDMO Production capacity expansion plan (21-23E) 38.22% 1260 Cubic metre RMB million 36.17% Gross profit margin 860 861 730 Revenue 671 Gross profit 311 279 2021 2022E 2024E l T02 plant’s equipment has been instal
Slide 13: Continue to Strengthen CMC Capacity Building
Continue to Strengthen CMC Capacity Building Revenue scale (21-22E) CMC staff (21-23E) 400 240 ～RMB 10 million 104 2021 2022E Internal and external two-pronged approach for 2021 2022E 2023E CMC diversion l Revenue of CMC: approx. RMB10 million, not yet achieved breakeven. 37% External BD l Order bac
Slide 14: Overview: EFS Investment & Incubation Business
Overview EFS Investment & Incubation Business RMB million 1419 1450 1350 l Completed 27 investments in 2021, of which 20 were newly-added 1250 l As of Dec 31, 2021, invested in a total of 87 portfolio companies with average 1150 equity holding around 19% 1047 1050 l Totient, a portfolio company, exi
Slide 15: Expanding Source of EFS Business, Covering Multiple Cutting-edge Areas
Expanding Source of EFS business, Covering Multiple Cutting-edge Area As of Dec 31, 2021, invested in a total of 87 portfolio companies l Reviewed 979 projects globally, added 20 biotech companies into the portfolio, made additional investment in 7 exiting portfolio companies in 2021 l Average equit
Slide 16: High-speed Pipeline Expansion & Smooth Progress in Financing
High-speed Pipeline Expansion & Smooth Progress in Financing 185 pipeline projects in portfolio companies • ANJ900 is about to initiate 185 phase III clinical trial; 2020 2020 • ANJ908 entered phase II 12 clinical trial 2021 2021 • VVN001 entered phase II clinical 125 trial 7 6 • Published phase II
Slide 17: PART 2: Financial Performance
PART 2: Financial Performance
Slide 18: Financial Performance of the Group
Financial Performance of the Group Rapid Growth in Revenue Adjusted Gross Profit 2104.1 666.8 Increased 201.9% Increased 110% 316.8 697 2020 2021 2020 2021 Adjusted EBITDA Adjusted EBITDA RMB million 552.5 352.5 Increased 39.7% Increased 63% 252.3 338.8 2020 2021 18 2020 2021
Slide 19: CRO BU Financial Statistics
CRO BU Financial Statistics CRO revenue Adjusted gross profit RMB million 740.4 343 Increased 68.7% Increased 63.6% 438.8 209.7 2020 2021 2020 2021 No. of CRO R&D personnel Annual revenue per CRO Personnel RMB’000 Increased 48.2% Increased 13.8% 1211 611 817 537 2020 2021 19 2020 2021
Slide 20: CDMO BU Financial Statistics
CDMO BU Financial Statistics Langhua’s revenue Langhua’s adjusted gross profit RMB million Decreased 10.17% Decreased 25.4% 1518 1363.6 434.4 328.8 2020 2021 2020 2021 20
Slide 21: Revenue Classifications of Principal Activities
Revenue Classifications of Principal Activities For the year ended December 31, 2021 CDMO and commercialisation Drug discovery services Total services Types of goods or services RMB’000 RMB’000 RMB’000 Revenue from non-investees 491,620 - 491,620 Full-time-equivalent (FTE) Fee-for-service (FFS) 117,
Slide 22: Items Measured at Fair Value with Changes Recognised in Profit or Loss
Items Measured at Fair Value with Changes in Fair Value Recognised in Profit or Loss The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows： RMB’000 At January 1, 2020 647,271 Acquired 171,381 Recognized from SFE revenue 51,297 Recognised from de
Slide 23: Capital Expenditure
Capital Expenditure l Group’s capital expenditure of RMB1059 million in 2021, used for the construction of various facilities l CDMP’s capital expenditure of approximately RMB218 million, used for new capacity construction, CMC laboratory construction, technology upgrade, etc. l Viva has many projec
Slide 24: PART 3: Future Strategies
CV iva PART 3: Future Strategies
Slide 25: Improve Capacity Building for Front-end Projects, Expand Whole Industry Chain Service
Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service Downstream To establish an open and cooperative Early-stage pre-clinical CFS CFS EFS EFS platform and a win-win ecosystem for global biopharmaceutical innovators service l Raise technology barriers
Slide 26: Q&A Session
CV iva Q&A Session
Slide 27: Thank You
THANK YOU！ IR@VIVABIOTECH.COM
Slide 28: APPENDIX: Adjusted Non-IFRS Net Profit
APPENDIX: Adjusted Non-IFRS Net Profit 2021 2020 2019 2018 RMB'000 RMB'000 RMB'000 RMB'000 Net Profit 300,560 -378,870 265,872 90,550 Add: fair value loss on financial liabilities at FVTPL -143,590 547,048 34,238 20,658 Add: interest expenses of the debt components of the Convertible Bonds 136,104 5